Filing Flows

Filing Flows › Companies › Utah Medical Products › Cash flow

Utah Medical Products cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$1.2M in Q2 2026 · $11.4M over twelve months

Operating cash flow$1.4M
Capital spending−$134K
Free cash flow+$1.2M
Cash / net income0.5×
Cash conversion cycle227 days

Analysis

In Q2 2026, Utah Medical Products generated $1.4M of operating cash flow and spent $134K on capital projects, leaving free cash flow of $1.2M. That is $1.6M less than in Q2 2025 ($2.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was $11.8M; the largest uses were dividends ($3.9M), buybacks ($1.9M), capital spending ($400K); the cash balance rose by $5.3M.

Operating cash flow was $1.4M against net income of $2.7M — 0.5× profit, less cash than reported earnings, worth checking against working capital. The largest differences: accrued liabilities −$1.1M, payables −$318K, inventory −$300K.

Its cash conversion cycle was 227 days (receivables 38 + inventory 214 − payables 25).

Free cash flow

Utah Medical Products: free cash flow by quarterUtah Medical Products: free cash flow by quarter$3.8MQ3 2024$2.9MQ4 2024$4.3MQ1 2025$2.8MQ2 2025$3.9MQ3 2025$3.4MQ4 2025$3.0MQ1 2026$1.2MQ2 2026
Operating cash flow less capital spending.
Utah Medical Products: operating cash flow against capital spendingUtah Medical Products: operating cash flow against capital spendingOperating cash flowCapital spending$3.9M$89KQ3 2024$2.9M$9KQ4 2024$4.5M$184KQ1 2025$2.9M$51KQ2 2025$3.9M$27KQ3 2025$3.5M$109KQ4 2025$3.1M$130KQ1 2026$1.4M$134KQ2 2026
Latest (Q2 2026): Operating cash flow $1.4M, Capital spending $134K.

Capital allocation, year by year

Utah Medical Products: where the cash came from (up) and went (down), by fiscal yearUtah Medical Products: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingBuybacksDividendsFY2021: Operating cash flow $21.2MFY2021: Shares issued $560KFY2021: Capital spending −$552KFY2021: Dividends −$11.5M$21.8MFY2021FY2022: Operating cash flow $21.1MFY2022: Shares issued $174KFY2022: Capital spending −$809KFY2022: Buybacks −$2.5MFY2022: Dividends −$3.2M$21.3MFY2022FY2023: Operating cash flow $22.3MFY2023: Shares issued $117KFY2023: Capital spending −$639KFY2023: Dividends −$4.3M$22.4MFY2023FY2024: Operating cash flow $14.8MFY2024: Shares issued $390KFY2024: Asset sales $27KFY2024: Capital spending −$230KFY2024: Buybacks −$20.0MFY2024: Dividends −$4.3M$15.2MFY2024FY2025: Operating cash flow $14.7MFY2025: Capital spending −$371KFY2025: Buybacks −$8.4MFY2025: Dividends −$4.0M$14.7MFY2025
Over these 5 years operating cash flow totalled $94.2M; the largest uses were buybacks ($30.8M) and dividends ($27.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$87.5M
Debtnone
Net cash$87.5M

Utah Medical Products funds itself: free cash flow was $11.4M over the last twelve months, with $87.5M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Utah Medical Products: sources (+) and uses (−) of cash, Q2 2026Utah Medical Products: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$1.4MDividends−$987KCapital spending−$134KCash drawn (+) / kept (−)−$122KBuybacks−$78KExchange rates−$62K
Utah Medical Products: sources (+) and uses (−) of cash, TTM to Q2 2026Utah Medical Products: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$11.8MCash drawn (+) / kept (−)−$5.3MDividends−$3.9MBuybacks−$1.9MCapital spending−$400KExchange rates−$304K

From profit to cash

Utah Medical Products: net income to operating cash flow, Q2 2026Utah Medical Products: net income to operating cash flow, Q2 2026Net income$2.7MDepreciation & amortization$226KStock-based pay$72KDeferred taxes−$21KReceivables$74KInventory−$300KPayables−$318KAccrued liabilities−$1.1MOperating cash flow$1.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20263821425227
Q1 20263721828227
Q4 20253719520212
Q3 20253417916197
Q2 20253517617194
Q1 20253718817208
Q4 20243921520234
Q3 20243419920213

Every quarter

QuarterOperating cash flowCapital spendingBuybacksDividendsCash drawn (+) / kept (−)Free cash flow
Q2 2026$1.4M−$134K−$78K−$987K−$122K$1.2M
Q1 2026$3.1M−$130K−$128K−$989K−$1.6M$3.0M
Q4 2025$3.5M−$109K−$994K−$977K−$1.5M$3.4M
Q3 2025$3.9M−$27K−$653K−$988K−$2.1M$3.9M
Q2 2025$2.9M−$51K−$3.5M−$1.0M$1.1M$2.8M
Q1 2025$4.5M−$184K−$3.2M−$1.0M−$349K$4.3M
Q4 2024$2.9M−$9K−$6.7M−$1.0M$5.5M$2.9M
Q3 2024$3.9M−$89K−$3.9M−$1.1M$767K$3.8M

Utah Medical Products: income statement and cash flow

Utah Medical Products, Q2 2026: revenue $8.5M (-14% year over year), operating margin 31.1%. The chart follows the revenue to costs, profit and cash.

Utah Medical Products: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.